Therefore, HMGB1 released by immunogenic chemotherapy may activate TLR2/6 signaling in DCs to suppress T-cell-mediated immunity rather than promote the T-cell-mediated immune response in COAD patients with defective TLR1. Here, TLR1 is linked to colon adenocarcinoma.